Acurx Pharmaceuticals IncNASDAQ:ACXP
- LAST PRICE1.3000
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.3500/ 13
- Ask / Lots1.3900/ 4
- Open / Previous Close--- / 1.3000
- Day Range---
- 52 Week Range
- Volume5,296
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACXP |
|---|---|---|
| 09:32 ET | 26401 | 1.45 |
| 09:33 ET | 3782 | 1.44 |
| 09:35 ET | 7131 | 1.41 |
| 09:37 ET | 7855 | 1.43 |
| 09:39 ET | 5794 | 1.44 |
| 09:42 ET | 1391 | 1.41 |
| 09:44 ET | 400 | 1.4101 |
| 09:46 ET | 13038 | 1.4094 |
| 09:48 ET | 3025 | 1.335 |
| 09:50 ET | 3312 | 1.32 |
| 09:51 ET | 2700 | 1.37 |
| 09:53 ET | 7750 | 1.36 |
| 09:55 ET | 200 | 1.3793 |
| 09:57 ET | 5654 | 1.341 |
| 10:00 ET | 800 | 1.36 |
| 10:04 ET | 838 | 1.3401 |
| 10:06 ET | 960 | 1.35 |
| 10:09 ET | 1143 | 1.3409 |
| 10:11 ET | 2672 | 1.35 |
| 10:13 ET | 1064 | 1.356 |
| 10:18 ET | 700 | 1.365 |
| 10:20 ET | 300 | 1.35 |
| 10:22 ET | 3193 | 1.375 |
| 10:24 ET | 500 | 1.3579 |
| 10:26 ET | 100 | 1.375 |
| 10:29 ET | 250 | 1.39 |
| 10:38 ET | 250 | 1.3799 |
| 10:42 ET | 100 | 1.38 |
| 10:44 ET | 5862 | 1.36 |
| 10:47 ET | 411 | 1.365 |
| 10:54 ET | 300 | 1.3573 |
| 10:56 ET | 1075 | 1.36 |
| 10:58 ET | 12146 | 1.35 |
| 11:00 ET | 200 | 1.36 |
| 11:02 ET | 1008 | 1.3601 |
| 11:03 ET | 200 | 1.36 |
| 11:05 ET | 300 | 1.3601 |
| 11:07 ET | 9408 | 1.34 |
| 11:09 ET | 2400 | 1.32 |
| 11:14 ET | 100 | 1.3001 |
| 11:23 ET | 272 | 1.3051 |
| 11:27 ET | 1680 | 1.2807 |
| 11:30 ET | 3410 | 1.299 |
| 11:32 ET | 2064 | 1.29 |
| 11:34 ET | 3369 | 1.305 |
| 11:45 ET | 3257 | 1.3 |
| 11:52 ET | 500 | 1.3002 |
| 11:59 ET | 2942 | 1.3001 |
| 12:08 ET | 7518 | 1.315 |
| 12:10 ET | 5000 | 1.315 |
| 12:12 ET | 8100 | 1.3 |
| 12:14 ET | 250 | 1.32 |
| 12:15 ET | 228 | 1.3267 |
| 12:21 ET | 5300 | 1.3299 |
| 12:28 ET | 3206 | 1.31 |
| 12:35 ET | 738 | 1.3 |
| 12:37 ET | 600 | 1.29 |
| 12:39 ET | 3265 | 1.285 |
| 12:44 ET | 10000 | 1.29 |
| 12:46 ET | 500 | 1.3 |
| 12:50 ET | 6920 | 1.2901 |
| 12:51 ET | 140 | 1.2949 |
| 12:53 ET | 2020 | 1.2938 |
| 12:55 ET | 4000 | 1.31 |
| 12:57 ET | 3400 | 1.291 |
| 01:02 ET | 2700 | 1.31 |
| 01:04 ET | 100 | 1.3199 |
| 01:08 ET | 100 | 1.3001 |
| 01:13 ET | 722 | 1.3 |
| 01:15 ET | 2753 | 1.285 |
| 01:33 ET | 200 | 1.3046 |
| 01:47 ET | 760 | 1.29 |
| 01:58 ET | 479 | 1.26 |
| 02:02 ET | 878 | 1.2901 |
| 02:07 ET | 1372 | 1.2815 |
| 02:16 ET | 144 | 1.3 |
| 02:32 ET | 216 | 1.28 |
| 02:38 ET | 182 | 1.2801 |
| 02:50 ET | 9688 | 1.33 |
| 02:52 ET | 150 | 1.3064 |
| 02:56 ET | 1636 | 1.31 |
| 02:59 ET | 580 | 1.3 |
| 03:03 ET | 100 | 1.3 |
| 03:10 ET | 1000 | 1.3101 |
| 03:12 ET | 250 | 1.3065 |
| 03:15 ET | 1000 | 1.305 |
| 03:17 ET | 900 | 1.3008 |
| 03:19 ET | 244 | 1.31 |
| 03:21 ET | 200 | 1.3099 |
| 03:24 ET | 1000 | 1.3001 |
| 03:30 ET | 5200 | 1.3 |
| 03:32 ET | 1220 | 1.3 |
| 03:33 ET | 464 | 1.284762 |
| 03:42 ET | 632 | 1.29 |
| 03:46 ET | 1600 | 1.2984 |
| 03:48 ET | 2538 | 1.3 |
| 03:50 ET | 591 | 1.3002 |
| 03:51 ET | 769 | 1.305 |
| 03:53 ET | 3293 | 1.305 |
| 03:55 ET | 995 | 1.301 |
| 03:57 ET | 8785 | 1.28 |
| 04:00 ET | 6773 | 1.3 |
Nov 20, 2024
DJ Acurx Pharmaceuticals Shares Slide 17% After Disclosing Bitcoin Investment, from 3:12PM ET on Wednesday Nov 20, 2024 by Dow Jones
3:12PM ET on Wednesday Nov 20, 2024 by Dow JonesAcurx Board of Directors Approves Bitcoin as Treasury Reserve Asset, from 7:01AM ET on Wednesday Nov 20, 2024 by Dow Jones
7:01AM ET on Wednesday Nov 20, 2024 by Dow Jones
Nov 18, 2024
Nov 14, 2024
DJ Acurx Pharmaceuticals Price Target Maintained With a $12.00/Share by HC Wainwright & Co., from 7:07AM ET on Thursday Nov 14, 2024 by Dow Jones
7:07AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Acurx Pharmaceuticals, Inc. Reports Third Quarter 2024 Results and Provides Business Update, from 7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
7:00AM ET on Wednesday Nov 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Acurx Pharmaceuticals Inc | 21.1M | -1.2x | --- |
GlycoMimetics Inc | 20.6M | -0.5x | --- |
X T L Biopharmaceuticals Ltd | 21.8M | -5.6x | --- |
Cocrystal Pharma Inc | 21.9M | -1.2x | --- |
NeuroBo Pharmaceuticals Inc | 20.2M | -0.5x | --- |
Aeon Biopharma Inc | 22.1M | -0.1x | --- |
Company Information
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.
Contact Information
- Headquarters
- 259 Liberty AvenueSTATEN ISLAND, NY, United States 10305
- Phone
- 917-533-1469
- Fax
- 302-636-5454
Executives
- Executive Chairman, Co-Founder, Managing Partner, Executive Director
- Robert Deluccia
- President, Chief Executive Officer, Co-Founder, Managing Director
- David Luci
- Co-Founder, Chief Financial Officer
- Robert Shawah
- Independent Director
- Jack Dean
- Independent Director
- James Donohue
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 16.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.81 |
EPS | $-1.09 |
Book Value | $0.32 |
P/E Ratio | -1.2x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
